QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Offers New Hope For The Treatment Of Corneal Blindness 0 comments
    Sep 16, 2013 5:52 PM | about stocks: ISCO

    International Stem Cell Corp. is known around the world for the thing that makes it unique in the stem cell industry: the company's proprietary platform for creating stem cells using parthenogenesis. It's an important development, since parthenogenesis results in pluripotent stem cells but doesn't involve the use of human embryos. Perhaps more importantly, it's a process that greatly reduces the immune matching problems commonly associated with the use of donor stem cells. As such, the company's technology represents a potential revolution in the generation and use of stem cells.

    In support of their ongoing research into possible applications of parthenogenetic stem cells, the company is aggressively pursuing studies relating to a number of diseases, including Parkinson's and liver disease. They are also involved in the development of human corneas from stem cells, primarily for anticipated use in the developing world where the need for corneal transplants is great. ISCO is the very first company to have successfully created 3-dimensional corneal tissue constructs from stem cells, and is now in a pre-clinical stage program for corneal development.

    There are an estimated 10 million people worldwide who are blind as the result of corneal damage, representing a large unmet need in the developing world. The cornea is a covering for the front of the eye. When disease or damage makes it opaque, vision is reduced or lost. Replacing damaged corneas with new ones is a well-established procedure, with a high rate of success, but it requires a source of corneas. Instead of depending upon donated corneas from deceased individuals, stem cell technology promises a bountiful new source for people all over the world.

    In addition to being used to treat disease, corneas can be developed as a research product in the drug testing market. ISCO's program will probably be commercialized through their subsidiary in India, in partnership with Insight Bioventures.

    For additional information, visit InternationalStemCell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.